Bearish
Pfizer stock declines 1.4% amid competitor's positive vaccine trial results
Pfizer's stock fell 1.4% to $27.41 on October 5, 2026, following Vaxcyte's announcement of positive results for a competing vaccine candidate. This development raises concerns about Pfizer's market share in the $3 billion to $6 billion vaccine market.
Key points
- Vaxcyte's vaccine trial success poses competitive threat to Pfizer.
- Pfizer's stock volume was 20% below average, indicating cautious investor sentiment.
- Analysts maintain a consensus 'Hold' rating for Pfizer with a $28.39 price target.
Sources
AI-generated from public news sources. Not financial advice.
